Results 211 to 220 of about 1,671,061 (305)

Engineered Peptide Self‐Assembled Nanofibers for Enhanced STING Activation: A Promising Nanodelivery Platform for Immunotherapy of Pediatric Solid Tumors

open access: yesAdvanced Science, EarlyView.
An engineered peptide self‐assembled nanofiber platform, designed to replicate STING–cGAMP binding motifs, facilitates pH‐responsive cytosolic delivery of cGAMP, enhances the endoplasmic reticulum with high efficiency, and robustly activates the STING pathway.
Yubin He   +6 more
wiley   +1 more source

PROTAC technology for sensitizing melanoma to immune checkpoint therapy. [PDF]

open access: yesJ Exp Clin Cancer Res
Zhou Q   +5 more
europepmc   +1 more source

Disentangling Heterogeneous Molecular Networks for Multi‐Omics‐Driven Cancer Driver Discovery

open access: yesAdvanced Science, EarlyView.
DRIVE integrates PPI topology and pan‐cancer multi‐omics profiles through dual‐view graph disentanglement, contrastive representation learning, and joint optimization. Across six PPI networks, DRIVE outperforms ten baselines and remains robust to structural and annotation perturbations.
Xinjing Gong   +8 more
wiley   +1 more source

Incidence and features of maculopapular rashes in patients receiving immune checkpoint inhibitors. [PDF]

open access: yesAn Bras Dermatol
Juan-Carpena G   +5 more
europepmc   +1 more source

CXCL3 Antagonism Reverses Systemic Antitumor Immune Memory Impairment Associated With High Tumor Burden and Sensitizes Anti‐PD‐1 Therapy

open access: yesAdvanced Science, EarlyView.
This study reveals that large tumors secrete more chemokine CXCL3, which recruits immunosuppressive neutrophils to the periphery, thereby impairing the activation and memory of systemic tumor‑reactive CD8+ T cells. CXCL3 antagonism restores systemic immune memory and enhances the antitumor efficacy of anti‑PD‑1 therapy, offering a potential strategy to
Ji Wang   +15 more
wiley   +1 more source

Simultaneous Quantification of Multiple Immune Checkpoint Interactions in Melanoma. [PDF]

open access: yesJ Clin Med
Cacho-Navas C   +12 more
europepmc   +1 more source

A Multi‐Targeting Chimeric Antigen Receptor‐T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non‐Small Cell Lung Cancer

open access: yesAdvanced Science, EarlyView.
A dual‐transmembrane Bicephali CAR‐T platform simultaneously targets CD276 and NKG2D ligands to address antigen heterogeneity in non‐small cell lung cancer. By improving immune synapse formation, mitochondrial fitness, antioxidant capacity, and stem‐like persistence, this design enhances durable tumor control and provides a versatile strategy to ...
Lina Wang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy